泼尼松龙可改善晚期乳腺癌对原发性内分泌治疗的反应。
Prednisolone improves the response to primary endocrine treatment for advanced breast cancer.
作者信息
Rubens R D, Tinson C L, Coleman R E, Knight R K, Tong D, Winter P J, North W R
机构信息
Imperial Cancer Research Fund, Clinical Oncology Unit, Guy's Hospital, London, UK.
出版信息
Br J Cancer. 1988 Nov;58(5):626-30. doi: 10.1038/bjc.1988.273.
Two hundred and twenty patients with progressive advanced breast cancer were given primary endocrine treatment (PET) according to menstrual status. Pre-menopausal patients received ovarian irradiation (O) and post-menopausal tamoxifen 10 mg bd (T). Patients were randomised to receive either no additional treatment or prednisolone 5 mg bd (P). Similar results were observed in each menstrual subgroup. In 194 evaluable patients, the response to PET + P was 49% and to PET alone 30% (P less than 0.01). P increased the median duration of response from 9 to 14 months (P less than 0.002) and the median time to disease progression from 5 to 9 months (P less than 0.001). Response to P after O or T alone occurred in only 2/62 (3%). Median survival in patients randomised to receive P at the outset of PET was prolonged by 4 months (P less than 0.05). The addition of P significantly improves the response to O or T in the treatment of advanced breast cancer.
220例进展期晚期乳腺癌患者根据月经状态接受了初始内分泌治疗（PET）。绝经前患者接受卵巢放疗（O），绝经后患者接受他莫昔芬10mg每日两次（T）。患者被随机分为不接受额外治疗或接受泼尼松龙5mg每日两次（P）。在每个月经亚组中观察到相似的结果。在194例可评估患者中，PET + P治疗的缓解率为49%，单纯PET治疗为30%（P<0.01）。P将缓解的中位持续时间从9个月延长至14个月（P<0.002），并将疾病进展的中位时间从5个月延长至9个月（P<0.001）。仅接受O或T治疗后对P有反应的患者仅2/62（3%）。在PET开始时随机接受P治疗的患者中位生存期延长了4个月（P<0.05）。添加P可显著改善晚期乳腺癌患者对O或T的反应。
Zotero 插件